Skip to main content

Advertisement

SpringerLink
Log in

The effect of mycophenolate mofetil on primary and secondary treatment of primary glomerulonephritis and lupus nephritis

  • Nephrology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Background

Mycophenolate mofetil (MMF) has shown to be a reliable choice in the treatment of glomerulonephritis. We retrospectively reviewed the clinical course and response to MMF therapy in 49 patients with primary glomerulopathy (37 patients) and lupus nephritis [class III (five patients) and IV (seven patients)].

Methods

Patients were treated with MMF for more than 6 months as a primary (18 patients) or an adjunctive treatment (31 patients). Patients were also on methylprednisolone (2–20 mg/day) and angiotensin converting enzyme inhibitor/angiotensin receptor blocker.

Results

The mean age of the patient cohort was 33.69 ± 12.4 years (range 19–59 years). Twenty-four-hour urinary protein excretion was reduced from 3.50 ± 3.08 g prior to the commencement of MMF drug therapy to 1.21 ± 1.44 and 0.99 ± 1.34 g at the sixth and 12th months of MMF therapy, respectively (P < 0.05 for all). During this same period, significant increases in serum total protein (from 5.92 ± 1.38 to 6.59 ± 0.79 and 6.81 ± 0.77 g/dl) and albumin levels (from 3.23 ± 1.10 to 3.93 ± 0.67 and 4.21 ± 0.50 g/dl) were detected, whereas total cholesterol and low-density lipoprotein levels were found to be significantly decreased (P < 0.05 for all). Serum creatinine levels did not significantly change. The efficacy of MMF in reducing proteinuria was similar in both first line and an adjunctive therapy. The efficacy of MMF therapy began at the third month of treatment and continued through to the 12th month.

Conclusion

Mycophenolate mofetil therapy was found to be useful in achieving improvements in proteinuria and nephrotic syndrome and stabilizing renal function. It was also a well-tolerated drug by the majority of the patients. Based on our results, we suggest that MMF may be alternative therapy for resistant/relapsing primary glomerulopathies and lupus nephritis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Eugui EM, Almquist SJ, Muller CD, Allison AC (1991) Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 33:161–173. doi:10.1111/j.1365-3083.1991.tb03746.x

    Article  PubMed  CAS  Google Scholar 

  2. Allison AC, Eugut EM, Sollinger HW (1993) Mycophenolate mofetil (RS-61443): mechanism of action and effects in transplantation. Transpl Rev 7:129–139. doi:10.1016/S0955-470X(05)80012-6

    Article  Google Scholar 

  3. Allison AC (1994) Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation. Transpl Proc 26:3205–3210

    CAS  Google Scholar 

  4. Allison AC, Kowalski WJ, Muller CJ et al (1993) Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transpl Proc 25[Suppl 2]:67–70

    CAS  Google Scholar 

  5. Chang C-CJ, Aversa G, Punnonen J et al (1993) Brequinar sodium, mycophenolic acid, and cyclosporin A inhibit different stages of IL-4 or IL 13 d human IgG4 and IgE production in vitro. Ann N Y Acad Sci 696:108–122

    Article  PubMed  CAS  Google Scholar 

  6. Blaheta RA, Leckel K, Wittig B, Zenker D, Oppermann E, Harder S et al (1999) Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells. Transpl Proc 31:1250–1252. doi:10.1016/S0041-1345(98)01984-8

    Article  CAS  Google Scholar 

  7. Sollinger HW (1995) Mycophenolate mofetil for prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 60:225–232. doi:10.1097/00007890-199508000-00003

    Article  PubMed  CAS  Google Scholar 

  8. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group (1996) A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61:1029–1037. doi:10.1097/00007890-199604150-00008

    Article  Google Scholar 

  9. Sheashaa HA, Bakr MA, Fouda MA, El-Dahshan KF, Ismail AM, Sobh MA et al (2007) Is it worth using daclizumab induction therapy with mycophenolate mofetil-based immunosuppressive regimens in live related donor kidney transplantation? A long-term follow up. Int Urol Nephrol 39(1):317–319. doi:10.1007/s11255-006-9091-8

    Article  PubMed  CAS  Google Scholar 

  10. Ojo AO, Meier-Kriesche HU, Hanson JA et al (2000) Mycophenolate mofetil reduces late renal allograft loss of acute rejection. Transplantation 69:2405–2409. doi:10.1097/00007890-200006150-00033

    Article  PubMed  CAS  Google Scholar 

  11. Mok CC, Lai KN (2002) Mycophenolate mofetil in lupus glomerulonephritis. Am J Kidney Dis 40:447–457. doi:10.1053/ajkd.2002.34882

    Article  PubMed  CAS  Google Scholar 

  12. Karim MY, Pisoni CN, Ferro L, Tungekar MF, Abbs IC, D’Cruz DP et al (2005) Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. Rheumatology (Oxford) 44:1317–1321. doi:10.1093/rheumatology/kei019

    Article  CAS  Google Scholar 

  13. Dooley MA, Cosio FG, Nachman PH, Falkenhain ME, Hogan SL, Falk RJ et al (1999) Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 10:833–839

    PubMed  CAS  Google Scholar 

  14. Tang S, Leung JC, Chan LY, Lui YH, Tang CS, Kan CH et al (2005) Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 68:802–812. doi:10.1111/j.1523-1755.2005.00460.x

    Article  PubMed  CAS  Google Scholar 

  15. Frutos MA, Lopez V, Alferez MJ, Aranda P (2005) Mycophenolate mofetil in high risk IgA glomerulonephritis. Nefrologia 25:387–392

    PubMed  CAS  Google Scholar 

  16. El-Reshaid K, El-Reshaid W, Madda J (2005) Combination of immunosuppressive agents in treatment of steroid-resistant minimal change disease and primary focal segmental glomerulosclerosis. Ren Fail 27:523–530. doi:10.1080/08860220500198623

    Article  PubMed  CAS  Google Scholar 

  17. Choi MJ, Eustace JA, Gimenez LF, Atta MG, Scheel PJ, Sothinathan R et al (2002) Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 61:1098–1114. doi:10.1046/j.1523-1755.2002.00214.x

    Article  PubMed  CAS  Google Scholar 

  18. Segarra A, Amoedo ML, Martinez Garcia JM, Pons S, Praga M, Garcia EI et al (2007) Efficacy and safety of ‘rescue therapy’ with mycophenolate mofetil in resistant primary glomerulonephritis—a multicenter study. Nephrol Dial Transpl 22(5):1351–1360. doi:10.1093/ndt/gfl805

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology, Faculty of Medicine, Cukurova University, 01330, Balcali-Adana, Turkey

    Saime Paydas, Cemal Kurt & Mustafa Balal

  2. Department of Nephrology, Faculty of Medicine, Inonu University, Malatya, Turkey

    Hulya Taskapan & Irem Pembegul

  3. Department of Biostatistics, Faculty of Medicine, Cukurova University, Balcali-Adana, Turkey

    Yasar Sertdemir

Authors
  1. Saime Paydas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cemal Kurt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hulya Taskapan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mustafa Balal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yasar Sertdemir
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Irem Pembegul
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Saime Paydas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paydas, S., Kurt, C., Taskapan, H. et al. The effect of mycophenolate mofetil on primary and secondary treatment of primary glomerulonephritis and lupus nephritis. Int Urol Nephrol 41, 145–152 (2009). https://doi.org/10.1007/s11255-008-9454-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-008-9454-4

Keywords

Search

Navigation